Skip to content

Central Mechanism Research of Human-Centered Acupuncture Intervention for Migraine?

Central Mechanism Research of Human-Centered Acupuncture Intervention for Migraine?

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000741
Enrollment
Unknown
Registered
2025-04-14
Start date
2025-02-10
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

control group:The basic acupoints selected included GV20, GB20, and Ashi points. For meridian differentiation, ST45 was chosen for Yangming meridian syndrome, GB44 for Shaoyang meridian syndrome, and
acupuncture group: Needling was performed at locations 1-2 cm lateral to the selected acupoints, specifically in non-meridian and non-acupoint areas, using superficial insertion without needle manipul

Sponsors

Dongzhimen Hospital of Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Meet the ICHD-3 diagnostic criteria for migraine without aura; 2) Age 18-65 years male or female right-handed; 3) A history of migraine for at least 1 year; 4) Frequency of migraine attacks at least 2 times per month; 5)No acupuncture treatment since the last 4 weeks and no medication with migraine preventive effects such as calcium channel blockers ß-blockers antidepressants and antiepileptic drugs; 6) The subjects themselves gave informed consent and voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Headache caused by organic disease or other types and locations; 2) Severe cranial anatomical asymmetry or definite lesions found in MRI scan; 3) Pacemakers aneurysm clips artificial heart valves ear implants metal fragments in the body; foreign objects in the eyes skin or body; or claustrophobia preventing completion of the MRI scan; 4) History of mental illness such as major depression bi-directional disorder schizophrenia; 5) History of alcohol or drug abuse/addiction in the last two years; 6)Any other systemic disease or uncertain condition that prevents completion of the programme.

Design outcomes

Primary

MeasureTime frame
Long-term efficacy;

Secondary

MeasureTime frame
Immediate efficacy;Duration of headache;Headache intensity;Quality of life;Change in headache intensity;Frequency of headache attacks;

Countries

China

Contacts

Public ContactWang Jun

Dongzhimen Hospital of Beijing University of Chinese Medicine

wangjunee@yeah.net15811480301

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026